ストックスクリーナーアプリを入手
22.30
0.45%
0.10
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™NORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey
Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nuplazid Exclusivity | ACAD Stock News - GuruFocus
US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN
Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Canada
Acadia wins patent appeal for key drug composition - Investing.com Australia
Acadia gets court approval related to Nuplazid patent - MSN
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review
ACAD Patent Victory Secures Nuplazid Exclusivity Till 2030 | ACAD Stock News - GuruFocus
US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case - BusinessLine
Acadia secures NUPLAZID patent protection through 2030 By Investing.com - Investing.com South Africa
Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ. - Law360
Acadia Pharmaceuticals (ACAD) Secures Patent Victory - GuruFocus
Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug - marketscreener.com
Federal Court Upholds Acadia Pharmaceuticals (ACAD) Patent Victo - GuruFocus
Transcript : ACADIA Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - marketscreener.com
Acadia gets court approval related to Nuplazid patent (ACAD) - Seeking Alpha
Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent - TipRanks
U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent - marketscreener.com
Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent - StreetInsider
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Yahoo Finance
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - Benzinga
JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $3 - GuruFocus
JPMorgan raises Acadia Pharmaceuticals stock price target to $30 - Investing.com Australia
ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from J - GuruFocus
ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from JP Morgan | ACAD Stock News - GuruFocus
JPMorgan raises Acadia Pharmaceuticals stock price target to $30 By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan - TipRanks
Insider Sell: Laura Brege Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts - Benzinga
ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Secu - GuruFocus
ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Securities | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - BioSpace
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals (ACAD) Receives Revised Price Target Amid Patent Victory | ACAD Stock News - GuruFocus
BofA Securities raises Acadia Pharmaceuticals stock price target to $23 - Investing.com Australia
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
BofA Securities raises Acadia Pharmaceuticals stock price target to $23 By Investing.com - Investing.com India
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surges 54% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace
Acadia Pharmaceuticals Holds Annual Meeting, Elects Directors - Investing.com Australia
Acadia Pharmaceuticals Holds Annual Meeting, Elects Directors By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th - GuruFocus
Acadia Pharmaceuticals Holds 2025 Annual Stockholder Meeting - TipRanks
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | ACAD Stock News - GuruFocus
The Escalator: Acadia Pharmaceuticals, Indivior, Takeda and more - Medical Marketing and Media
Acadia Pharmaceuticals hires new SVP for Rare Disease unit By Investing.com - Investing.com India
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise - BioSpace
Acadia Pharmaceuticals hires new SVP for Rare Disease unit - Investing.com
0.92%
7.75%
大文字化:
|
ボリューム (24 時間):